Press Release

October 26, 2009

READING, MA – InfoMedics, Inc., a company that engages patients and physicians to communicate better through the delivery of treatment feedback, has poster presentations at three industry conferences in October 2009. All of these studies provide a unique look at real-life patient feedback regarding experiences with medications for chronic conditions including ulcerative colitis (UC) and attention-deficit/hyperactivity disorder (ADHD) in adults and children.

The presentation at the Annual Meeting of the American College of Gastroenterology, October 26-28, San Diego, CA, is the first detailed study of the 'real-life' perceptions and experiences of patients beginning and continuing a new course of 5-aminosalicylic acid (5-ASA), the mainstay of treatment for UC.

"As patients with UC frequently require life-long treatment, the attitudes and experiences of patients beginning a new course of treatment may play an important role in aiding adherence," said InfoMedics' Senior Director of Analytic Services Donna Kerney, PhD, who co-authored the poster with Shire Pharmaceuticals, Inc. "In this study, we examined patients' experiences with the 5-ASA drug MMX^® mesalamine. The results were quite positive: the majority of patients reported that this treatment reduced UC symptom severity and disruption of daily activities, with 81% of patients reporting that they would continue to take MMX mesalamine after the patient experience program."

"One of the results we find of particular value is the high adherence rate of patients who participated in the patient experience program: 88% of patents reported that they were fully adherent with MMX mesalamine therapy throughout this program (i.e. took their medication every day, as prescribed). We believe this is attributable not only to the efficacy of the drug in question, but to the wealth of information and tools provided to participants," continued Dr. Kerney. "Disease education and follow-up questions were a part of the baseline survey, including strategies for managing UC and how MMX mesalamine works, dealing with active disease (termed 'flare-ups' in the survey), impact of food on disease relapse, support groups, and when to notify their doctor about abdominal pain. Patient feedback programs help physicians and patients understand the 'big picture' for each individual patient, assisting them in overcoming many of the most common adherence hurdles."

Earlier this month, InfoMedics presented three patient feedback studies focused on the effects of lisdexamfetamine dimesylate (LDX; Vyvanse^®, Shire US Inc.), a long-acting prodrug stimulant indicated for attention-deficit/hyperactivity disorder (ADHD). Two of the studies focused on the adult population and were presented at the 61st American Psychiatric Association Institute on Psychiatric Services; October 8-11, New York, NY. Another study focused on the pediatric population was presented at the 21st Annual International Conference on AD/HD (CHADD), October 7-10, Cleveland, OH. These studies presented data gathered through The New Start Survey Program which provides physicians with "real world" perceptions from parents of children with ADHD and adults regarding the effects of treatment on bothersome symptoms of ADHD throughout the day, and aspects of satisfaction with current treatment compared with prior treatment regimens.

"Patient feedback programs are designed to not only inform physicians about whether drugs are alleviating symptoms, but also to see the 'real-world' impact on their patients' daily lives," said Dr. Kerney. "In the case of the pediatric ADHD study presented at CHADD, parents of children taking lisdexamfetamine dimesylate (LDX) reported significantly less interference of ADHD symptoms with their child's family interactions, social interactions, homework, and school activities. It is this kind of information that helps to build a more 'whole-patient' picture for physicians that goes beyond what can realistically be achieved solely through office visits. InfoMedics prides itself on significantly enhancing patient-physician communication, the benefits of which can include building brand credibility and loyalty, encouraging patient-physician dialogue, extending patient ownership and reinforcing the prescribed treatment regimen."

Dr. Kerney's coauthors were as follows:

Annual Meeting of the American College of Gastroenterology

• Troy Hamilton, PharmD; Michael Sumner, MD; Dory Sullivan, MD: Shire Pharmaceuticals Inc.
• Neema Patel, Independent Consultant
• Medical writing support was provided by Duncan Campbell (GeoMed) with financial support from Shire Pharmaceuticals Inc. This research was funded by Shire Pharmaceuticals Inc.

21st Annual International Conference on AD/HD (CHADD)

• Patrick Hunt, PharmD, Jill Slater, PharmD: Shire Development Inc.
• Donna Antonucci, MD, Private Practice
• Frank A. Lopez, MD, Children's Developmental Center, Winter Park, FL
• Michael Manos, PhD, Children's Hospital, Cleveland Clinic, Cleveland, OH
• Writing and editorial assistance provided by Michael Pucci, PhD, and Samantha Cappuccino-Williams of Health Learning Systems, part of CommonHealth^®
• Supported by funding from Shire Development Inc.

61st American Psychiatric Association Institute on Psychiatric Services

• Michael Manos, PhD, Children's Hospital, Cleveland Clinic, Cleveland, OH
• Frank A. Lopez, MD, Children's Developmental Center, Winter Park, FL
• Donna Antonucci, MD, Private Practice
• Writing and editorial assistance provided by Michael Pucci, PhD, and Samantha Cappuccino-Williams of Health Learning Systems, part of CommonHealth^®
• Supported by funding from Shire Development Inc.

About InfoMedics
InfoMedics, Inc. works with biopharmaceutical marketers to break down walls that exist in health communications and enable doctors and patients to better communicate about a treatment experience. We facilitate this communication by inviting patients to provide feedback to their prescribing physician and then deliver that feedback in a meaningful format directly to the physician. Patient feedback is invited through existing brand message channels and then delivered through a voice and web platform. Our goal is to help physicians make more informed choices and patients to have a better care experience. Our approach is rooted in behavioral science which enables our biopharmaceutical clients to learn what makes some patients stick to the treatment plan, while others stop.

InfoMedics works with the world's top pharmaceutical companies, with brands, large and small, and at all stages and challenges that arise during the product lifecycle. Years of experience has generated proven results: the company's programs increase brand awareness and loyalty among prescribing physicians and improves adherence among prescribed patients.

For additional information contact:
Ariane Doud
Matter Communications
978-499-9250 x239
ariane@matternow.com

Amy Weickert
InfoMedics, Inc.
781-904-4512
aweickert@infomedics.com